It is widely accepted that COX-2 has an important role in the stimulation of inflammation and tumorigenesis in hypoxic cancer cells [13, 14], and the COX-2-selective inhibitor has been considered a potential candidate which can disturb the angiogenic signaling cascade upstream of HIF-1α-VEGF expression [15–17]. Here, HIF1A is linked to cancer.